Cubist Pharmaceuticals, Inc. (CBST) Tops Q2 EPS by 22c

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) reported Q2 EPS of $0.23, $0.22 better than the analyst estimate of $0.01. Revenue for the quarter came in at $294.4 million versus the consensus estimate of $299.6 million.

For earnings history and earnings-related data on Cubist Pharmaceuticals, Inc. (CBST) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c